Controversial effects of exogenous testosterone on cardiovascular diseases

American Journal of Therapeutics

Volumn 23, Issue 6, 2016, Pages e1504-e1513

  Al Khazaali, Ali ^a   Arora, Rohit ^b   Muttar, Saad ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c BENEDICTINE UNIVERSITY   (United States)

Author keywords

Androgen replacement therapy; Cardiovascular diseases; Testosterone

Indexed keywords

ANDROGEN; GEL; TESTOSTERONE;

AGED; CARDIOVASCULAR DISEASES; ENDOCRINE SYSTEM DISEASES; GEL; HUMAN; MALE;

AGED; ANDROGENS; CARDIOVASCULAR DISEASES; ENDOCRINE SYSTEM DISEASES; GELS; HUMANS; MALE; TESTOSTERONE;

EID: 84995743482     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000212     Document Type: Article

References (44)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 129:e28-e292. Available at: http://circ.ahajournals.org/cgi/ pmidlookup?view5long&pmid524352519 Accessed July 19, 2014.
2. Nelson HD, Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive services task force recommendations. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 May. Report No.: 12-05168-EF-1. Available at: http://www.ncbi.nlm.nih.gov/books/ NBK97827/pdf/TOC.pdf. Accessed July 19, 2014.
3. Maric C. Sex differences in cardiovascular disease and hypertension: involvement of the renin-angiotensin system. Hypertension. 2005;46:475-476. Epub August 15, 2005. Available at: http://hyper.ahajournals. org/content/46/3/475.full.pdf. Accessed July 19, 2014.
4. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-5926. Available at: http://press.endocrine.org/doi/pdf/10. 1210/jc.2003-031719. Accessed July 20, 2014.
5. US Census Bureau. US interim projections by age, sex, race, and hispanic origin. 2012. Available at: http:// www.census.gov/newsroom/releases/archives/ population/cb12-243.html. Accessed July 20, 2014.
6. Seftel AD. Male hypogonadism. Part I: epidemiology of hypogonadism. Int J Impot Res. 2006;18:115-120. Available at: http://www.nature.com/ijir/journal/v18/n2/ pdf/3901397a.pdf. Accessed July 20, 2014.
7. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173:1465-1466.
8. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab. 1997; 82:682-685. Available at: http://press.endocrine.org/doi/full/10.1210/jcem.82.2. 3766. Accessed July 20, 2014.
9. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a metaanalysis study. Int J Androl. 2011;34:528-540. Epub October 24, 2010.
10. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39-46. Epub December 7, 2009.
11. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1-7. Available at: http://www.ncbi.nlm.nih. gov/pubmed/12809074. Accessed July 22, 2014.
12. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-906. Available at: http://ejeonline. org/content/154/6/899. Accessed July 24, 2014.
13. Heufelder AE, Saad F, Bunck MC, et al. Fifty-two week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30:726-733. Epub July 3, 2009.
14. Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602-612.
15. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail. 2007;9:44-50.
16. Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828-837. Available at: http://care.diabetesjournals.org/content/34/4/828.full. pdf+html. Accessed July 26, 2014.
17. Sonmez A, Taslipinar A, Tapan S, Serdar MA. Comment on: Jones et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care. 2011;34:828-837.
18. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic fractures in men) study in Sweden. J Am Coll Cardiol. 2011;58:1674-1681.
19. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-769.
20. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with betacatenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006;147:141-154.
21. Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol. 2009; 51:303-313. Epub October 6, 2009.
22. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90: 871-876. Available at: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC1768369/. Accessed July 20, 2014.
23. Whitsel EA, Boyko EJ, Matsumoto AM, et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001;111:261-269. DOI: http://dx.doi.org/10.1016/S0002-9343(01)00833-6.
24. Brown GA, Vukovich MD, Martini ER, et al. Endocrine responses to chronic androstenedione intake in 30-to 56-year-old men. J Clin Endocrinol Metab. 2000;85: 4074-4080.
25. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989;261:1165-1168.
26. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:280-293.
27. Haddad R, Kennedy C, Caples S, et al. Testosterone and cardiovascular risk in men: a systemic review and metaanalysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;81:29-39. DOI: http://dx.doi.org/10. 4065/82.1.29.
28. Tan KC, Shiu SW, Kung AW. Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clin Endocrinol (Oxf). 1999;51:765-769.
29. Herbst KL, Amory JK, Brunzell JD, et al. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003;284:E1112-E1118. Available at: http://ajpendo.physiology.org/content/284/6/E1112. full-text.pdf+html. Accessed July 25, 2014.
30. Webb CM, Adamson DL, de Zeigler D, et al. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 83:437-439. doi:10. 1016/S0002-9149(98)00880-7.
31. Rosano GM, Leonardo F, Pagnotta P, et al. Acute antiischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666-1670. doi: 10.1161/01.CIR.99.13.1666.
32. Jaffe MD. Effect of testosterone on postexercise ST segment depression. Br Heart J. 1977;39:1217-1222. Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC483399/pdf/brheartj00237-0055.pdf. Accessed August 30, 2014.
33. Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl). 1993;106:415-418. Available at: http://www.cmj.org/ch/reader/view-abstract. aspx?volume5106&issue56&start5415. Accessed July 29, 2014.
34. English KM, Steed RP, Diver MJ, et al. Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation. 2000;102:1906-1911. Available at: http://circ.ahajournals.org/content/ 102/16/1906.full.pdf+html. Accessed July 29, 2014.
35. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122. Epub June 30, 2010.
36. FDA Drug Safety Communication. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Available at: http://www.fda.gov/Drugs/ DrugSafety/ucm383904.htm. Accessed August 5, 2014.
37. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
38. Cappola AR. Testosterone therapy and risk of cardiovascular disease in men. JAMA. 2013;310:1805-1806.
39. Dupree JM, Ramasamy R, Kovac JR, et al. Re: Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. Eur Urol. 2014;66:175-176.
40. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9: e85805. eCollection 2014.
41. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014. Epub ahead of print.
42. FDA adding general warning to testosterone products about potential for venous blood clots. Available at: http://www.fda.gov/drugs/drugsafety/ucm401746.htm. Accessed January 26, 2015.
43. Available at: http://minnesotanaturalmedicine.com/ blog/fda-weighs-testosterone. Accessed October 17, 2014.
44. Available at: www.ema.europa.eu/ema/index.jsp?curl5pages/news-and-events/news/2014/10/news- detail-002187.jsp&mid5WC0b01ac058004d5c1. Accessed October 17, 2014.